TABLE 1.

Effect of tedizolid/rifampicin combination on MRSA clinical isolates.

	Rifampicin + tedizolid (2 mg/L)		Rifampicin + tedizolid (4 mg/L)
	% of biofilm biomass	% of rifampicin-resistant strains	% of biofilm biomass	% of rifampicin-resistant strains
MRSA Isolate 1	67.64.1	0	61.52.8	0
MRSA Isolate 2	58.93.8	0	40.74.7	0
MRSA Isolate 3	73.13.8	0	62.52.7	0

Percentages of biofilm biomass and rifampicin-resistant CFU of 48-h-old biofilm of 3 clinically isolated MRSA strains after 48 h of treatment with two combinations of tedizolid plus rifampicin. Biofilm biomass was evaluated using the crystal violet staining method and compared to untreated controls. Rifampicin-resistant CFU were evaluated by plating biofilm onto TSA plates containing 20 μg/mL rifampicin. Results are expressed as mean ± SEM of a single experiment with three technical replicates. Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus.